Journal of Neuroimaging · 2019 · 42 citations · 29 references
MedicineOncologyRadiologyDiagnostic ImagingDiagnostic RadiologyMolecular OncologyBrain TumorsGlioblastomaMagnetic Resonance ImagingMedical ImagingTumor CharacterizationTumor ImagingCancer ImagingGlioblastoma BiomarkersGlioblastoma ImagingGlioblastoma PrognosisHistogram AnalysisIsocitrate Dehydrogenase MutationsMagnetic ResonanceMorphologic Diagnostic Criteria
ABSTRACT BACKGROUND AND PURPOSE Telomerase reverse transcriptase (TERT) promoter mutations are associated with worse prognosis in glioblastoma. The purpose of this study was to evaluate whether TERT mutation status was associated with specific morphologic and quantitative imaging features. METHODS Twenty‐nine patients with isocitrate dehydrogenase 1/2‐wildtype glioblastoma (13 TERT‐wildtype, 16 TERT‐mutated), who underwent preoperative magnetic resonance (MR) imaging were included in this retrospective study. Qualitative imaging phenotypes were evaluated using the Visually Accessible Rembrandt Images (VASARIs) feature set. Histogram analysis of apparent diffusion coefficient (ADC) and dynamic contrast‐enhanced MR perfusion values were performed on enhancing tumor volumes‐of‐interest, and differences between TERT‐wildtype and TERT‐mutated tumors were assessed. RESULTS VASARI analysis demonstrated that the majority of morphologic features were not significantly different between TERT‐wildtype and TERT‐mutated tumors, although a higher proportion of TERT‐wildtype tumors featured nonenhancing tumor crossing midline ( P = .014). TERT‐mutated tumors demonstrated lower median rate constant k ep (.38 vs. .76, P = .03) and lower median volume transfer coefficient K trans (.13 vs. .31, P = .02). There was no significant difference in median plasma volume v p ( P = .92) or ADC values ( P = .66) between the two groups. We further found a significant interaction between median k ep and K trans and TERT status, respectively, suggesting greater risk of death with increasing blood‐brain barrier dysfunction in TERT‐mutated but not in TERT‐wildtype tumors. CONCLUSION Our study demonstrates evidence of altered permeability metrics associated with TERT mutation in glioblastoma, laying the foundation for future prospective studies assessing implications for therapeutic management and clinical outcomes.
29
<i>TERT</i> Promoter Mutations in Familial and Sporadic Melanoma
Susanne Horn, Adina Figl, P. Sivaramakrishna Rachakonda et al. · Science · 2013 · 1.8K citations
Patrick Killela, Zachary J. Reitman, Yuchen Jiao et al. · Proceedings of the National Academy of Sciences · 2013 · 1.4K citations · Full text
TERT promoter mutations in primary and secondary glioblastomas
Naosuke Nonoguchi, Takashi Ohta, Jieun Oh et al. · Acta Neuropathologica · 2013 · 262 citations